Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticleCurrent Practice

Pain patch

Dori Seccareccia
Canadian Family Physician September 2007, 53 (9) 1447-1448;
Dori Seccareccia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Anne was a 68-year-old woman with pancreatic cancer. She had epigastric abdominal pain that had responded well to immediate-release morphine and was using 5-mg tablets approximately 4 times daily. A friend told her about a “pain patch” that worked well. Anne, who disliked taking pills and was interested in the convenience of changing a patch only every 3 days, made an appointment to see her family physician to discuss the transdermal fentanyl patch. She decided to try it and was started on a 25-μg patch every 3 days. After day 3 of using the patch, Anne’s son informed her physician that his mom had become somnolent, confused, and had fallen. She was taken to the emergency department and was admitted. Her patch was discontinued and she was given 650 mg of acetaminophen to take by mouth every 4 hours as needed for pain. Three days later, she was having a great deal of pain and was neither somnolent nor confused. The son was understandably very concerned about his mom’s condition.

It is common for patients to ask about pain patches. Up until quite recently, the 25-μg dose was the smallest available via patch. Even though the 12-μg patch is approved for sale in Canada, it is not always available at every pharmacy nor universally covered by provincial drug plans. (Note: Although this patch delivers 12.5 μg/h of fentanyl, it is called “12” to avoid confusion with 125 μg/h.) Patches should not be cut nor occluded to obtain a lower dose. If they have not been using opioids, patients should not be given even the lowest doses of fentanyl via patch.1 There are various examples where tragic consequences resulted when opioid-naïve patients were started on low doses of the transdermal fentanyl patch.2

It is also not always simple to convert from an oral opioid to the transdermal fentanyl patch. To rotate to the fentanyl patch from another opioid, it is best to determine the equivalent oral morphine dose that the patient is taking. Moving from the total daily oral morphine equivalent to the correct dose of transdermal fentanyl can be a challenge. One method to determine the dose of the patch is to use the conversion table in the Compendium of Pharmaceuticals and Specialties (CPS), which states that 60 to 134 mg of oral morphine is equivalent to a 25-μg patch. This range is very broad owing to the variability in absorption among patients2 and could lead to underdosing.1 The conversion table in the CPS is recommended only for converting to the fentanyl patch and not from the patch to an alternative opioid, as one could overestimate the dose of the new opioid.1

There are many other conversion methods. In one alternative method, Breitbard recommends using 2 mg of oral morphine as equivalent to 1 μg of fentanyl3; therefore, 50 mg of oral morphine within 24 hours is equivalent to a 25-μg fentanyl patch. Another commonly used conversion is to equate 100 mg of oral morphine to a 25-μg fentanyl patch.2

No matter which method is used, the most important point to remember is to start low and go slow. This is especially true for the frail elderly and debilitated patients. Pharmacokinetics might be altered because of minimal fat stores, muscle wasting, altered clearance rates, improper administration, and non-adherent patches.1 In addition, absorption of fentanyl might be increased in a hot environment. It is also important to remember that when titrating the dose, the shortest titration period is 3 days because of the extended time required for the plasma concentrations of the drug to stabilize.4

Anne was restarted on oral morphine and was using approximately 30 mg of oral morphine daily. She was eventually started on a 12-μg patch. After being discharged from the hospital, Anne did very well for 6 weeks, then her pain began to increase. She used acet-aminophen as a breakthrough analgesic when the pain intensified, but it did little to reduce the pain.

Breakthrough medication

It is important for patients using the fentanyl patch to be given breakthrough pain medication, as well. Any opioid in the correct dose can be used as a breakthrough or rescue dose. It is not uncommon to use a breakthrough dose that is approximately 10% of the daily opioid dose.5 In this case, Anne uses a 12-μg patch, which is approximately equivalent to 12 mg of subcutaneous (SC) morphine within 24 hours or 24 mg of oral morphine within a 24-hour period (using the Breitbart formula previously mentioned).3 This would be approximately equal to 2.5 mg of oral morphine.

The breakthrough 2.5-mg dose of morphine every 1 hour as needed greatly helped Anne. At first she used only 1 to 3 breakthrough doses a day. Unfortunately, as her disease progressed, so did her pain. Once she required up to 10 breakthrough doses a day, she called her physician.

The number of breakthrough doses can help to determine when a strength of the fentanyl patch should be increased. For example, Anne used 25 mg of breakthrough oral morphine within 24 hours. This dose is equivalent to another 12 μg of fentanyl delivered via patch, which would now make her likely to tolerate a 25-μg patch. It is important to realize that, when changing the dose of the patch, it takes 13 to 24 hours for the fentanyl to reach the new therapeutic drug level. It is also important to remember that, when the patch dose is increased, the breakthrough dose will also need to be increased. Once Anne was on the 25-μg patch, her breakthrough dose would also require adjusting. The 25-μg patch is equivalent to 50 mg of morphine by mouth in 24 hours. Ten percent of 50 mg is 5 mg, so a reasonable new breakthrough dose would be 5 mg every 1 hour as needed.

Anne did quite well again for a few weeks, then she began to deteriorate. The family physician now visited her at home for terminal care.

Transition to end-of-life care

Fentanyl patches are not ideal for terminal care. As discussed earlier, it takes a relatively long time to change the dose. More rapid adjustments might be necessary in the last hours to days, so you’d likely start SC opioids (morphine or hydromorphone).

Anne was now using a 25-μg patch and was using 20 mg of morphine breakthrough medication by mouth each day. In order to assess her need for SC morphine, we calculated her total daily dose of morphine. The 25-μg patch is equivalent to 25 mg of SC morphine in 24 hours. The 20 mg of breakthrough medication by mouth is equivalent to 10 mg of SC morphine. Therefore, in total, Anne required 35 mg of SC morphine in 24 hours.

Once the fentanyl patch is discontinued, it is best not to start the continuous dose of morphine for 18 to 24 hours, as the fentanyl continues to be released from the SC fat stores into the blood for up to 24 hours. Once the fentanyl is removed, SC breakthrough medications can be used until the standing dose of morphine is initiated between 18 and 24 hours after patch removal. The morphine can be delivered by intermittent SC injections or by continuous SC injections. With each method, an SC breakthrough medication needs to be made available.

Anne was very comfortable on intermittent SC injections of morphine (6.0 mg every 4 hours and 3.0 mg every half hour as needed for breakthrough). She died peacefully approximately 2 weeks after SC injections were initiated.

Notes

BOTTOM LINE

  • Patients who have not been using opioids should not be started on a fentanyl patch.

  • When rotating to a fentanyl patch, it is important to start low and go slow, especially in elderly or debilitated patients.

  • The shortest titration period is 3 days because of the extended time required for the plasma concentrations of the drug to stabilize.

  • Fentanyl patches are not ideal for end-of-life care, especially when there is uncontrolled pain.

POINTS SAILLANTS

  • Il ne faut pas commencer l’administration du timbre de fentanyl aux patients qui n’ont pas encore utilisé des opioïdes.

  • Lorsqu’on passe à un timbre de fentanyl, il est important de commencer à faible dose et lentement, surtout chez les personnes plus âgées et affaiblies.

  • Le dosage le plus court est de 3 jours en raison de la longueur de temps nécessaire pour que les concentrations plasmatiques du médicament se stabilisent.

  • Les timbres de fentanyl ne sont pas ce qu’il y a de mieux pour les soins en _n de vie, surtout lorsque la douleur n’est pas contrôlée.

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Repchinsky C
    Duragesic (fentanyl transdermal delivery system); Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties 2007. Ottawa, ON: Canadian Pharmacists Association; 2007. Product Monograph; p. 782.
  2. ↵
    Prescription Information Services of Manitoba. Transdermal fentanyl: pitfalls in drug therapy. Spectrum: a drug information newsletter for pharmacists. 2005 March [Accessed 2007 June 6]. Available from: http://www.prisminfo.org.
  3. ↵
    1. Breitbart W,
    2. Chandler S,
    3. Eagel B,
    4. Ellison N,
    5. Enck RE,
    6. Lefkowitz M,
    7. et al
    . An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. Oncology 2000;14(5):695-705.
    OpenUrlPubMed
  4. ↵
    1. Jeal W,
    2. Benfield P
    . Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997;53(1):109-38.
    OpenUrlPubMed
  5. ↵
    1. Downing GM,
    2. Wainwright W
    . Medical care of the dying. 4. Victoria, BC: Victoria Hospice Society; 2006. p. 179.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 53 (9)
Canadian Family Physician
Vol. 53, Issue 9
1 Sep 2007
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pain patch
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pain patch
Dori Seccareccia
Canadian Family Physician Sep 2007, 53 (9) 1447-1448;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Pain patch
Dori Seccareccia
Canadian Family Physician Sep 2007, 53 (9) 1447-1448;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Breakthrough medication
    • Transition to end-of-life care
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Scurvy
  • Intraprofessional relationships
  • Answer: Answer to Ophthaproblem
Show more Current Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire